Advertisement

Topics

GammaCan Company Profile

21:36 EDT 20th September 2017 | BioPortfolio

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan’s initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan’s first product was entered to phase-II clinical trials.GammaCan’s innovative treatment is based on intravenous Immunoglobulin (IVIg), a safe, non-toxic human plasma-based product currently used and approved for treating a number of immune deficiencies and autoimmune diseases. GammaCan focuses on treating patients in the five years following initial therapy, with the aim of preventing recurrence of disease caused by micrometastasis (single cells left in the body following surgery and chemotherapy). Publications in medical literature by GammaCan scientists and researchers state that IVIg appears to profoundly impact cancer progression in patients being treated with IVIg for immune and autoimmune diseases while concurrently suffering from cancer.GammaCan is constantly looking for new clinical-stage candidates. We have developed the necessary mechanisms and capabilities to efficiently identify, evaluate and execute in-licensing deals. Recognizing that many smaller start-up companies in Israel and Europe lack the financial resources to complete clinical trials, we offer these enterprises a development track for their molecules, thus allowing them to focus on continued development of their platforms and technologies.

Location

440 Ninth Avenue 17th Floor, Suite 1720
New York
New York
10001
United States of America

Contact

Phone: 1 212 404 1911
Fax: 1 212 404 1450
Email: CDemonte@aol.com


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

GammaCan

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan’s initial therapy under development is a first-in-class anti-cancer immunotherapy aimed ...

More Information about "GammaCan" on BioPortfolio

We have published hundreds of GammaCan news stories on BioPortfolio along with dozens of GammaCan Clinical Trials and PubMed Articles about GammaCan for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GammaCan Companies in our database. You can also find out about relevant GammaCan Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record